Blume was appointed to both the audit committee and the technology committee. Previously, Blume held the position of vice chairman for Deloitte, where she was a partner until retirement in 2015.
At Deloitte, Blume worked in a broad range of industries to transform business through the implementation of technology. Throughout her Deloitte career, she held numerous leadership positions, including serving as a member of the firm's US executive committee.
Centene provides a portfolio of services to government sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals.
Many receive benefits provided under Medicaid in addition to other state-sponsored programs, Medicare, dual eligible programs and programs with the US Department of Defense and US Department of Veterans Affairs.
The company also provides healthcare services to groups and individuals delivered through commercial health plans. It operates local health plans and offers a range of health insurance solutions.
Centene also contracts with other healthcare and commercial organizations to provide specialty services including behavioral health management, care management software, correctional healthcare services, dental benefits management, in-home health services, life and health management, managed vision, pharmacy benefits management, specialty pharmacy and telehealth services.
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar
Novo Nordisk expands legal action over compounded 'semaglutide'
Neuraxpharm launches Neuraxpharm Australia
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
iOncologi acquires TargImmune Therapeutics
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'